Yes. UnitedHealthcare covers Spravato (esketamine) for treatment-resistant depression in Massachusetts when prior authorization criteria are met (per UHC PA/Medical Necessity Policy 2025 P 2168-10, effective May 1, 2025). UHC's commercial Spravato PA, when approved, runs for 12 months on first issuance — among the longer initial authorizations among Massachusetts commercial payers.
Across Lumin Health's 2026 commercial Spravato (esketamine) authorizations: 100% approval rate, with a median 4-day decision turnaround. Lumin Health's pre-submission medical-necessity review and standardized clinical documentation packet contribute to this outcome. Individual approval depends on plan-specific PA criteria — see UnitedHealthcare's policy summary below.
Latest medical review on: May 5th, 2026. Medically reviewed by Instructor in Psychiatry at Harvard Medical School and Lumin Health Co-founder, Chief Medical Officer Dr. Ben Yudkoff.
UnitedHealthcare's commercial Spravato coverage is governed by UHC PA/Medical Necessity Policy 2025 P 2168-10 (effective May 1, 2025; last P&T review 3/2025):
This summary applies to UnitedHealthcare commercial medical plans. UHC Community Plan (UnitedHealthcare's MassHealth-managed-care product) operates under separate Medicaid criteria, not commercial PA. Lumin Health verifies your specific plan during your consultation.
Note: Lumin Health delivers Spravato (esketamine) — FDA-approved nasal spray — and intramuscular (IM) ketamine. Lumin Health does not deliver intravenous (IV) ketamine.
Massachusetts requires commercial insurers to cover mental health services on parity with medical/surgical benefits under Chapter 175 Section 47B and federal MHPAEA. This means UnitedHealthcare cannot apply more restrictive prior authorization, visit limits, or cost-sharing to Spravato than to comparable medical treatments. For MassHealth fee-for-service members, Spravato coverage follows the MassHealth Drug List criteria; for UnitedHealthcare Community Plan members (UHC's MassHealth managed-care product), coverage follows UHC's Community Plan policy. Both are separate from the commercial policy. Lumin Health verifies your specific plan at consultation.
Two Massachusetts statutes are particularly relevant when a commercial insurer reviews a Spravato prior authorization:
The "deemed granted" rule. Under 211 CMR 52.07, a Massachusetts commercial carrier that fails to respond to a complete prior authorization request within two business days is deemed to have granted the authorization. This applies to all major Massachusetts commercial carriers — Aetna, Blue Cross Blue Shield of Massachusetts, Cigna, Harvard Pilgrim Health Care, Mass General Brigham Health Plan, UnitedHealthcare, and the Group Insurance Commission's contracted carriers.
External review through the Office of Patient Protection. If your commercial insurer denies a Spravato authorization, you have the right to request external review by the Health Policy Commission's Office of Patient Protection (OPP). The filing window is four months from the final internal denial; OPP issues decisions within 45 days. Historically, more than 40% of OPP external reviews resolve in the patient's favor — an unusually patient-favorable rate compared with most states' insurance-department-administered review processes.
Spravato treatment at Lumin Health is available at all four Massachusetts locations: Newton, Cambridge, Woburn, and Brookline. All Lumin Health Spravato locations are REMS-certified per FDA requirements.
How UnitedHealthcare compares with other major Massachusetts commercial payers on published Spravato prior authorization criteria:
Each linked cell opens the full Lumin Health Spravato coverage page for that payer.
Yes — UHC requires PA for the Spravato medication under its commercial PA/Medical Necessity Policy 2168-10. Lumin Health submits the PA request directly to UnitedHealthcare on your behalf.
Two different antidepressant medications or treatment regimens, each at the maximally tolerated dose for at least 8 weeks. UHC reduced this requirement from three to two in March 2025 per its policy change-control entry. Augmentation regimens (antipsychotics, lithium, or thyroid hormone) count as qualifying trials.
12 months. Reauthorization runs at the same 12-month interval, with current symptom-rating documentation demonstrating remission or clinical response.
Lumin Health handles everything on your behalf so you don't have to worry. If your prior authorization is denied, our team manages the appeal process directly with UnitedHealthcare — you don't need to navigate the paperwork or follow-ups. See the appeal section below for the full pathway.
Yes — UHC follows FDA labeling for both indications. For the MDD-with-acute-suicidal-ideation indication, Spravato must be used in combination with a newly initiated or optimized oral antidepressant.
Step 1 — File a Level 1 internal appeal. Deadline: 180 days from the date on the Explanation of Benefits (per UHC: "The first request for an appeal should be sent to UnitedHealthcare no later than 180 days after you receive the EOB, unless your plan allows a longer time period."). Note: a small number of UHC commercial plans use a stricter 65-day appeal window — verify on your specific EOB. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Members: file via memberforms.uhc.com or mail per the address printed on your EOB. Phone: Member Services number on your ID card. Providers: file through UHC Provider Portal at uhcprovider.com.
Step 2 — Peer-to-peer (P2P) review. UHC offers peer-to-peer review with strict timing: per UHC, P2P requests for inpatient cases must be submitted within 3 business days of denial; outpatient cases within 21 calendar days. Your prescriber contacts the UHC clinical reviewer named in the denial letter.
Step 3 — Expedited (urgent) appeal. UHC must resolve expedited (urgent) appeals within 72 hours when delay jeopardizes the member's health. Member or treating provider calls UHC and explicitly requests expedited review with documented medical urgency.
Appeal levels. UHC uses a two-step process: (1) claim reconsideration request, then (2) formal appeal if reconsideration is unsatisfactory. After the second step, members have the right to external review.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Massachusetts external review is administered by the Health Policy Commission's Office of Patient Protection (OPP). Filing window: 4 months from the final internal denial. Decision timeline: 45 days. See Massachusetts state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. UHC routes behavioral-health benefits through Optum Behavioral Health (formerly United Behavioral Health). If your Spravato denial originated on the BH benefit, the Optum BH appeal pathway applies. Most commercial Spravato denials are processed under the medical benefit and follow the standard UHC pathway. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the UnitedHealthcare medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
Step 1 — File a Level 1 internal appeal. Deadline: 180 days from the date on the Explanation of Benefits (per UHC: "The first request for an appeal should be sent to UnitedHealthcare no later than 180 days after you receive the EOB, unless your plan allows a longer time period."). Note: a small number of UHC commercial plans use a stricter 65-day appeal window — verify on your specific EOB. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Members: file via memberforms.uhc.com or mail per the address printed on your EOB. Phone: Member Services number on your ID card. Providers: file through UHC Provider Portal at uhcprovider.com.
Step 2 — Peer-to-peer (P2P) review. UHC offers peer-to-peer review with strict timing: per UHC, P2P requests for inpatient cases must be submitted within 3 business days of denial; outpatient cases within 21 calendar days. Your prescriber contacts the UHC clinical reviewer named in the denial letter.
Step 3 — Expedited (urgent) appeal. UHC must resolve expedited (urgent) appeals within 72 hours when delay jeopardizes the member's health. Member or treating provider calls UHC and explicitly requests expedited review with documented medical urgency.
Appeal levels. UHC uses a two-step process: (1) claim reconsideration request, then (2) formal appeal if reconsideration is unsatisfactory. After the second step, members have the right to external review.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Massachusetts external review is administered by the Health Policy Commission's Office of Patient Protection (OPP). Filing window: 4 months from the final internal denial. Decision timeline: 45 days. See Massachusetts state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. UHC routes behavioral-health benefits through Optum Behavioral Health (formerly United Behavioral Health). If your Spravato denial originated on the BH benefit, the Optum BH appeal pathway applies. Most commercial Spravato denials are processed under the medical benefit and follow the standard UHC pathway. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the UnitedHealthcare medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
